The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder

Liu, Wanying; Zhang, Fuxu; Zheng, Yingxia; Shen, He; Zhang, Tianhong; Guo, Qian; Xu, Hua; Chen, Haiying; Liu, Caiping; Yu, Shunying; Jiang, Kaida; Li, Huafang; Li, Guanjun; Wang, Xiaoliang; Liu, Xiaohua

doi:10.1016/j.neulet.2021.136184

Cited by 11 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, miRNAs can cross the blood-brain barrier (20, 21), potentially via exosomes (22)(23)(24), and assessment of differential miRNA expression in blood has been used to identify surrogate blood-based biomarkers in brain diseases, including Alzheimer's disease, depression, and cancer (25)(26)(27). Brain-specific miRNAs identified in peripheral blood have been proposed as markers for traumatic brain injury (28).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA–mRNA networks are dysregulated in opioid use disorder postmortem brain: Further evidence for opioid-induced neurovascular alterations

et al. 2023

View full text Add to dashboard Cite

IntroductionTo understand mechanisms and identify potential targets for intervention in the current crisis of opioid use disorder (OUD), postmortem brains represent an under-utilized resource. To refine previously reported gene signatures of neurobiological alterations in OUD from the dorsolateral prefrontal cortex (Brodmann Area 9, BA9), we explored the role of microRNAs (miRNA) as powerful epigenetic regulators of gene function.MethodsBuilding on the growing appreciation that miRNAs can cross the blood-brain barrier, we carried out miRNA profiling in same-subject postmortem samples from BA9 and blood tissues.ResultsmiRNA–mRNA network analysis showed that even though miRNAs identified in BA9 and blood were fairly distinct, their target genes and corresponding enriched pathways overlapped strongly. Among the dominant enriched biological processes were tissue development and morphogenesis, and MAPK signaling pathways. These findings point to robust, redundant, and systemic opioid-induced miRNA dysregulation with a potential functional impact on transcriptomic changes. Further, using correlation network analysis, we identified cell-type specific miRNA targets, specifically in astrocytes, neurons, and endothelial cells, associated with OUD transcriptomic dysregulation. Finally, leveraging a collection of control brain transcriptomes from the Genotype-Tissue Expression (GTEx) project, we identified a correlation of OUD miRNA targets with TGF beta, hypoxia, angiogenesis, coagulation, immune system, and inflammatory pathways.DiscussionThese findings support previous reports of neurovascular and immune system alterations as a consequence of opioid abuse and shed new light on miRNA network regulators of cellular response to opioid drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA–mRNA networks are dysregulated in opioid use disorder postmortem brain: Further evidence for opioid-induced neurovascular alterations

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Therefore, through controlling stress-induced neural plasticity and neuronal survival in depression, miRNA-132 may have an impact on the onset and progression of depression. Moreover, Li et al mentioned that miR-182 levels were negatively correlated with BDNF levels in patient serum [101], which was consistent with the trend of miR-132/BDNF [100], perhaps these two miRNAs regulate depression by jointly targeting BDNF, though the precise mechanism needs to be further explored.…”

Section: Patient Body Fluids and Exosomesmentioning

confidence: 67%

“…Regarding peripheral blood miR-132, it was shown that [98,99] depressed patients had significantly higher levels of miR-132 expression in peripheral blood leukocytes and plasma than did healthy controls, which is consistent with the expression trend in CUMS rat models. MiR-132 has also been demonstrated to be a known regulator of BDNF [100]. Therefore, through controlling stress-induced neural plasticity and neuronal survival in depression, miRNA-132 may have an impact on the onset and progression of depression.…”

Section: Patient Body Fluids and Exosomesmentioning

confidence: 99%

Research progress of miRNA in different depression model samples

Zhang¹

2022

AETR

View full text Add to dashboard Cite

Depression is a mood disorder characterized by prolonged depressed mood, lack of interest and pleasure, and low self-assessment. The miRNAs, as single-stranded non-coding RNA molecules that can participate in post-transcriptional regulation of gene expression, regulate physiological processes by degrading mRNAs or inhibiting the translation of their target genes to achieve gene silencing. Numerous studies have revealed an in-depth understanding of depression-related miRNA changes and the role they play in the pathogenesis of depression, and miRNAs have received widespread attention as therapeutic targets. This review summarizes the expression of miRNAs in different depression samples (patients, rats, and mice) and the corresponding regulatory pathways. The analysis revealed the existence of miRNAs with consistent expression trends in different samples, and the discovery of these miRNAs provides new insights into their use as therapeutic targets in depression.

show abstract

“…As an example, blood miRNA levels were shown to largely correlate with brain expression [ 55 ]. Indeed, miRNA circulating levels are a promising field of investigation [ 56 - 60 ]. Access to cerebrospinal fluid could reduce this bias [ 61 , 62 ], however feasibility is obviously a strong limitation.…”

Section: Potential Limitations Of Biomarkersmentioning

confidence: 99%

Clinical Utility of Fluid Biomarker in Depressive Disorder

Serretti

2022

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Major depressive disorders are ranked as the single largest contributor to non-fatal health loss and biomarkers could largely improve our routine clinical activity by predicting disease course and guiding treatment. However there is still a dearth of valid biomarkers in the field of psychiatry. The initial assumption that a single biomarker can capture the myriad of complex processes proved to be naive. The purpose of this paper is to critically review the field and to illustrate the possible practical application for routine clinical care. Biomarkers derived from DNA analysis are the ones that have received the most attention. Other potential candidates include circulating transcription products, proteins, and inflammatory markers. DNA polygenic risk scores proved to be useful in other fields of medicine and preliminary results suggest that they could be useful both as risk and diagnostic biomarkers also in depression and for the choice of treatment. A number of other possible fluid biomarkers are currently under investigation for diagnosis, outcome prediction, staging, and stratification of interventions, however research is still needed before they can be used for routine clinical care. When available, clinicians may be able to receive a lab report with detailed information about disease risk, outcome prediction, and specific indications about preferred treatments.

show abstract

The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder

Cited by 11 publications

References 35 publications

MicroRNA–mRNA networks are dysregulated in opioid use disorder postmortem brain: Further evidence for opioid-induced neurovascular alterations

MicroRNA–mRNA networks are dysregulated in opioid use disorder postmortem brain: Further evidence for opioid-induced neurovascular alterations

Research progress of miRNA in different depression model samples

Clinical Utility of Fluid Biomarker in Depressive Disorder

Contact Info

Product

Resources

About